LIVALO
Pronunciation: pit-a-va-STAT-in


What it isHMG-CoA reductase inhibitor; hyperlipidemia.
Why this oneMinimal CYP metabolism, so it is an option with protease inhibitors and other strong inhibitors where most statins are restricted.
What limits itModerate potency only. Cyclosporine is contraindicated; cost is higher than the generics.
Animated chart of estimated U.S. prescriptions per year, Lipid-lowering meds (1955–2026). Pitavastatin enters in 2010 (estimated).
Principal riskMyopathy; contraindicated with cyclosporine
Legacy pregnancy categoryX
Defining liabilityMyopathy/rhabdomyolysis and hepatotoxicity; interaction burden varies by agent.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Primary hyperlipidemia / mixed dyslipidemia (LDL-C lowering) | Adults & peds ≥8 yr | 2 mg QD | 2–4 mg QD | 4 mg QD |
Titration Reassess LDL-C after ≥4 weeks before adjusting
Renal Moderate/severe impairment & ESRD on HD: start 1 mg QD, max 2 mg QD
Hepatic Contraindicated in acute liver failure or decompensated cirrhosis
Available strengths
Pregnancy Discontinue when pregnancy recognized; may cause fetal harm (mechanism-based)
Lactation Breastfeeding not recommended during treatment
Generic entry2031 est.
Open Pitavastatin in the interactive console ↗

Open Pitavastatin in the interactive console ↗